Related Experiment Video
Updated: Oct 18, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Activated Histone Acetyltransferase p300/CBP-Related Signalling Pathways Mediate Up-Regulation of NADPH Oxidase,
Alexandra-Gela Lazar1, Mihaela-Loredana Vlad1, Adrian Manea1
1Institute of Cellular Biology and Pathology, "Nicolae Simionescu" of the Romanian Academy, 050568 Bucharest, Romania.
Abstract:
Accumulating evidence implicates the histone acetylation-based epigenetic mechanisms in the pathoetiology of diabetes-associated micro-/macrovascular complications. Diabetic kidney disease (DKD) is a progressive chronic inflammatory microvascular disorder ultimately leading to glomerulosclerosis and kidney failure. We hypothesized that histone acetyltransferase p300/CBP may be involved in mediating diabetes-accelerated renal damage. In this study, we aimed at investigating the potential role of p300/CBP in the up-regulation of renal NADPH oxidase (Nox), reactive oxygen species (ROS) production, inflammation, and fibrosis in diabetic mice. Diabetic C57BL/6J mice were randomized to receive 10 mg/kg C646, a selective p300/CBP inhibitor, or its vehicle for 4 weeks. We found that in the kidney of C646-treated diabetic mice, the level of H3K27ac, an epigenetic mark of active gene expression, was significantly reduced. Pharmacological inhibition of p300/CBP significantly down-regulated the diabetes-induced enhanced expression of Nox subtypes, pro-inflammatory, and pro-fibrotic molecules in the kidney of mice, and the glomerular ROS overproduction. Our study provides evidence that the activation of p300/CBP enhances ROS production, potentially generated by up-regulated Nox, inflammation, and the production of extracellular matrix proteins in the diabetic kidney. The data suggest that p300/CBP-pharmacological inhibitors may be attractive tools to modulate diabetes-associated pathological processes to efficiently reduce the burden of DKD.
Insights
Histone acetyltransferase p300/CBP inhibitors reduce kidney damage in diabetic mice by decreasing inflammation and oxidative stress. This suggests p300/CBP inhibitors may treat diabetic kidney disease.
Area of Science:
- Epigenetics
- Nephrology
- Diabetology
Background:
- Epigenetic mechanisms, specifically histone acetylation, are implicated in diabetic complications.
- Diabetic kidney disease (DKD) is a chronic inflammatory condition leading to kidney failure.
- The role of histone acetyltransferase p300/CBP in diabetes-accelerated kidney damage is under investigation.
Purpose of the Study:
- To investigate the role of p300/CBP in regulating renal NADPH oxidase (Nox), reactive oxygen species (ROS) production, inflammation, and fibrosis in diabetic mice.
- To assess the therapeutic potential of p300/CBP inhibition in mitigating DKD.
Main Methods:
- Diabetic C57BL/6J mice were treated with a selective p300/CBP inhibitor (C646) or vehicle for 4 weeks.
- Kidney tissues were analyzed for levels of histone acetylation marks (H3K27ac), Nox subtypes, pro-inflammatory and pro-fibrotic molecules, and ROS production.
Main Results:
- C646 treatment significantly reduced H3K27ac levels in the kidneys of diabetic mice.
- Pharmacological inhibition of p300/CBP down-regulated diabetes-induced expression of Nox subtypes, inflammatory and fibrotic molecules.
- Glomerular ROS overproduction was significantly reduced by C646 treatment.
Conclusions:
- p300/CBP activation contributes to ROS production, inflammation, and fibrosis in the diabetic kidney.
- Inhibition of p300/CBP effectively modulates diabetes-associated pathological processes.
- p300/CBP inhibitors show promise as a therapeutic strategy for reducing the burden of DKD.
More Related Videos
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024